
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. demonstrates a promising financial outlook supported by its innovative approach to immunotherapy and increased guidance metrics. The company's proprietary PREDATOR platform and INDUKINE molecules position it at the forefront of cancer treatment, potentially increasing its competitive edge in the biopharmaceutical market. Additionally, the reported increase in key financial metrics, alongside improving demand drivers, reflects a robust business model poised for growth amidst the evolving landscape of cancer therapeutics.
Bears say
Werewolf Therapeutics Inc faces a challenging outlook due to a decline in revenues, which have decreased by 30 basis points year-over-year, while expenses increased by 3.8%, leading to a net operating income decrease of 2.6%. Additionally, the average effective rental rate has dropped by 50 basis points year-over-year, impacted by a 4.8% reduction in new lease rates, indicating potential weakness in new business generation. The slowdown in new lease rate growth suggests that demand is not keeping pace with existing supply, which could hinder overall financial stability and recovery for the company.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares